Literature DB >> 8952533

Inducible and endothelial nitric oxide synthase expression during development of transplant arteriosclerosis in rat aortic grafts.

L M Akyürek1, B C Fellström, Z Q Yan, G K Hansson, K Funa, E Larsson.   

Abstract

In the vascular system, distinct isoforms of nitric oxide synthase (NOS) generate nitric oxide (NO), which acts as a biological messenger. Its role in the development of transplant arteriosclerosis (TA) is still unclear. To investigate whether NO is involved in TA, we studied the expression of NOS isoforms, inducible NOS (iNOS) and endothelial NOS (eNOS), by immunohistochemistry and in situ hybridization during the first two post-transplantation months and their relation with cold ischemia (1 to 24 hours) and reperfusion injury using an aortic transplantation model in the rat. We found an increased iNOS expression in the intima and adventitia and a decreased expression in the media, whereas eNOS expression was not significantly altered during the development of TA. Co-localization studies suggested that iNOS-positive cells were vascular smooth muscle cells, monocyte-derived macrophages, and endothelial cells. Prolonged ischemic storage time resulted in an increase in eNOS expression in the neointima. In situ hybridization showed iNOS mRNA expression by vascular cells in the neointima and media. NO produced by iNOS and eNOS may be involved, at least in part, in the pathogenesis of TA in aortic grafts. Additional studies are needed to confirm the modulatory mechanism of NO during the development of TA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8952533      PMCID: PMC1865349     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  36 in total

Review 1.  Nitric oxide, a novel biologic messenger.

Authors:  C J Lowenstein; S H Snyder
Journal:  Cell       Date:  1992-09-04       Impact factor: 41.582

2.  Graft-infiltrating cell nitric oxide production is stimulated by TNF alpha.

Authors:  J M Langrehr; R L Simmons; R A Hoffman
Journal:  Transplant Proc       Date:  1992-12       Impact factor: 1.066

3.  Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase.

Authors:  D S Bredt; P M Hwang; C E Glatt; C Lowenstein; R R Reed; S H Snyder
Journal:  Nature       Date:  1991-06-27       Impact factor: 49.962

4.  Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium.

Authors:  M W Radomski; R M Palmer; S Moncada
Journal:  Lancet       Date:  1987-11-07       Impact factor: 79.321

5.  Chronic rejection of rat renal allografts. II. The impact of prolonged ischemia time on transplant histology.

Authors:  S Yilmaz; T Paavonen; P Häyry
Journal:  Transplantation       Date:  1992-04       Impact factor: 4.939

6.  Nonradioactive in situ hybridization using digoxigenin-labeled oligonucleotides. Applications to musculoskeletal tissues.

Authors:  I D Crabb; S S Hughes; D G Hicks; J E Puzas; G J Tsao; R N Rosier
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

7.  Interferon-gamma and tumor necrosis factor synergize to induce nitric oxide production and inhibit mitochondrial respiration in vascular smooth muscle cells.

Authors:  Y Geng; G K Hansson; E Holme
Journal:  Circ Res       Date:  1992-11       Impact factor: 17.367

8.  Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells.

Authors:  R Sarkar; E G Meinberg; J C Stanley; D Gordon; R C Webb
Journal:  Circ Res       Date:  1996-02       Impact factor: 17.367

9.  Nitric oxide synthesis in the in vivo allograft response: a possible regulatory mechanism.

Authors:  J M Langrehr; R A Hoffman; T R Billiar; K K Lee; W H Schraut; R L Simmons
Journal:  Surgery       Date:  1991-08       Impact factor: 3.982

10.  Ischemic injury before heart transplantation does not cause coronary arteriopathy in experimental isografts.

Authors:  P Masetti; V J DiSesa; F J Schoen; S C Sun; J G Byrne; R F Appleyard; R Laurence; L H Cohn
Journal:  J Heart Lung Transplant       Date:  1991 Jul-Aug       Impact factor: 10.247

View more
  7 in total

1.  Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis.

Authors:  L L Shears; N Kawaharada; E Tzeng; T R Billiar; S C Watkins; I Kovesdi; A Lizonova; S M Pham
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

2.  Inducible nitric oxide synthase expression in coronary arteries of transplanted human hearts with accelerated graft arteriosclerosis.

Authors:  A Lafond-Walker; C L Chen; S Augustine; T C Wu; R H Hruban; C J Lowenstein
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

3.  Role of nitric oxide in experimental obliterative bronchiolitis (chronic rejection) in the rat.

Authors:  E A Kallio; P K Koskinen; E Aavik; K Vaali; K B Lemstöm
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

4.  Prevention of the expression of inducible nitric oxide synthase by a novel positive inotropic agent, YS 49, in rat vascular smooth muscle and RAW 264.7 macrophages.

Authors:  Y J Kang; E B Koo; Y S Lee; H S Yun-Choi; K C Chang
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

5.  Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression.

Authors:  J Jankowski; M van der Giet; V Jankowski; S Schmidt; M Hemeier; B Mahn; G Giebing; M Tolle; H Luftmann; H Schluter; W Zidek; M Tepel
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

6.  Filamin B deficiency in mice results in skeletal malformations and impaired microvascular development.

Authors:  Xianghua Zhou; Fei Tian; Johan Sandzén; Renhai Cao; Emilie Flaberg; Laszlo Szekely; Yihai Cao; Claes Ohlsson; Martin O Bergo; Jan Borén; Levent M Akyürek
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-26       Impact factor: 11.205

7.  Tolerance induction ameliorates allograft vasculopathy in rat aortic transplants. Influence of Fas-mediated apoptosis.

Authors:  L M Akyürek; C Johnsson; D Lange; P Georgii-Hemming; E Larsson; B C Fellström; K Funa; G Tufveson
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.